Are you ready to unlock the secrets of successful deal making in the dynamic world of pharma and biotech? Join us for an intensive and practical 1-day course that will equip you with the essential skills and knowledge needed to navigate the complex landscape of licensing, partnerships, and negotiations.
At our course, you will learn from industry experts who have a deep understanding of the valuation approaches, risk assessment methodologies, and deal structuring techniques that are currently shaping the pharma-biotech world. We have carefully designed the agenda to cover all the crucial topics, ensuring that you leave with a comprehensive understanding of the deal-making process.
Dimitri has over 35 years’ experience in the pharmaceutical and biotech industry. Over the last 20 years, he is the founder and Managing Director of DyoDelta Biosciences, an advisory company specializing in providing support in putting together corporate collaborations in the Life Sciences.
He has been involved in over 200 pharma/biotech agreements, mostly cross-border transactions and has been a speaker or chairman in 40 conferences.
He is a co-founder and former CEO of ImmuPharma plc, a drug development biotech company listed on AIM of the London Stock Exchange and previously on Euronext in Brussels.
His past roles include Senior Director, Worldwide Business Development at GlaxoSmithKline, where he was responsible for worldwide transactions with a focus on licensing novel products for development and commercialization. He wa also the head for transactions in Europe at Bristol-Myers Squibb. Prior to that, he spent 8 years at Procter & Gamble when it had a pharmaceutical division, in senior marketing, R&D and business development positions and began his career in marketing in Marketing at Novartis in 1987.
He has 2 degrees from the University of London - a Bachelor’s in Biochemistry from Kings College and a Master’s in Pathology (Faculty of Medicine) from Imperial College Medical School and training in Internal Medicine and Neurology from Harvard Medical School. He is a Fellow of the Royal Society of Medicine, the Royal Society of Chemistry, the Royal Society of Biology, the Institute of Biomedical Science, and a member of the British Pharmacological Society, the British Neuroscience Association and the British Society for Immunology.
This condensed 1-day course provides a comprehensive overview of the key aspects of deal making in the pharma and biotech industry, as well as MedTech and Digital Health. Participants gain valuable insights into the deal-making process, including preparation, due diligence, licensing, IP protection, valuation, negotiation, and relationship management.